CMV program -  Spinoff Redvax sold to Pfizer

Redbiotec has successfully developed a CMV vaccine program based on its rePAX® technology. This program was sold to Pfizer. See Pfizer press release, January 5 2014. Pfizer press release.

“Through the acquisition of the Redvax innovative CMV vaccine platform and expertise we will seek to develop a vaccine to prevent a difficult disease that can have a devastating and lifelong impact on young children,” said Kathrin U. Jansen, a senior vice president of Pfizer.

See also investor statement Redalpine blog.


New focus: Herpesviruses, Influenza and exploratory projects

Redbiotec is participant of an EU program targeting a universal Influenza vaccine.

After the successful transaction with Pfizer, in which Redbiotec’s spinoff Redvax GmbH was sold, Redbiotec has now moved in further herpesvirus fields such as HSV-2.

Beyond the vaccine activities Redbiotec is currently exploring opportunities for the application of its rePAX® platform int the area of pain and microorganisms.


Redbiotec at J.P. Morgan 34th Healthcare Conference in SF
Schlieren, 20 November 2015
Redbiotec will attend JPM 34th Healthcare Conference in San Francisco starting January 11 2016. Redbiotec's delegation will include the two projects leaders of Redbiotec's HSV-2 vaccine and Universal Flu vaccine programs.
Leading HSV expert joins Redbiotec
Schlieren, 30 June 2015
Redbiotec announces today the appointment of Professor & Director Lbachir BenMohamed from UC Irvine, School of Medicine, to Redbiotec's team. Professor BenMohamed is a leading expert in immunology and in particular in the field of the Herpes Simplex Virus HSV.
Further news